IONETIX
GenericsIONETIX is a generic drug manufacturer focused on Oncology. Key products include GALLIUM GA 68 GOZETOTIDE.
IONETIX's Key Drugs
IONETIX's core commercial portfolio centers on GALLIUM GA 68 GOZETOTIDE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
IONETIX's Recent FDA Approvals
New NDA/BLA approvals for IONETIX over the last two years — novel drugs only, excluding generics and label supplements.
IONETIX's Therapeutic Areas
IONETIX's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IONETIX's Top Competitors
IONETIX's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IONETIX Pipeline Snapshot
Active clinical trials for IONETIX across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GALLIUM GA 68 GOZETOTIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-12-21
- Latest
- 2026-05-14
- Applications
- 2